Transthyretin amyloidosis has long puzzled researchers precisely because the protein behaves so stably under normal physiological conditions — yet it causes devastating cardiac and neurological damage in millions of aging adults worldwide. Understanding how a remarkably stable protein manages to misfold at all has been a central unanswered question in amyloid biology, and new structural evidence now offers a credible answer.
Published in PNAS, this work identifies an alternative denaturation pathway for transthyretin (TTR), the tetrameric transport protein responsible for carrying thyroid hormone and retinol through the bloodstream. Under physiological pH, TTR denatures exceptionally slowly — a kinetic barrier that has made its aggregation behavior paradoxical. The research demonstrates that TTR can access a distinct unfolding route that bypasses the conventional rate-limiting step, effectively allowing the protein to reach aggregation-competent states without following the expected slow denaturation kinetics. This alternative pathway provides a mechanistic bridge between TTR's apparent stability and its clinical propensity to form amyloid fibrils in cardiac tissue, peripheral nerves, and other organs.
This finding carries meaningful implications for the broader TTR amyloidosis field, which has seen significant therapeutic advances in recent years — including RNA interference agents and small-molecule tetramer stabilizers like tafamidis. Most existing drugs work by reinforcing TTR's tetrameric structure to prevent dissociation and unfolding along the classical pathway. If a second denaturation route exists, it raises the possibility that some patients progress despite treatment because therapy-resistant misfolding continues via this alternative channel. That hypothesis remains to be tested, and it is critical to note this appears to be mechanistic, likely in-vitro biochemistry rather than a human clinical study. The finding is nonetheless conceptually significant — it reframes how the field thinks about TTR stability and could inform next-generation therapeutic design targeting the newly characterized pathway.